• Consensus Rating: Hold
  • Consensus Price Target: $3.00
  • Forecasted Upside: 104.08%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.47
+0 (0.00%)
Get New Epizyme Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EPZM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EPZM

Analyst Price Target is $3.00
▲ +104.08% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Epizyme in the last 3 months. The average price target is $3.00, with a high forecast of $6.00 and a low forecast of $1.50. The average price target represents a 104.08% upside from the last price of $1.47.

This chart shows the closing price for EPZM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 4 polled investment analysts is to hold stock in Epizyme. This rating has held steady since March 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
8/15/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
11/13/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
2/11/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
5/12/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/10/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/8/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/7/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/6/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/27/2022CowenDowngradeOutperform ➝ Market Perform$1.50Low
6/27/2022CowenDowngradeOutperform ➝ Market Perform$1.50Low
6/27/2022WedbushDowngradeOutperform ➝ NeutralLow
6/3/2022HC WainwrightLower TargetBuy$8.00 ➝ $6.00High
5/12/2022HC WainwrightLower Target$10.00 ➝ $8.00High
3/2/2022HC WainwrightLower TargetBuy$15.00 ➝ $10.00High
8/10/2021HC WainwrightLower TargetBuy$36.00 ➝ $15.00High
8/9/2021Morgan StanleyDowngradeEqual Weight ➝ Underweight$10.00 ➝ $5.00High
5/7/2021Morgan StanleyLower TargetEqual Weight$11.00 ➝ $10.00High
5/7/2021SVB LeerinkUpgradeMarket Perform ➝ Outperform$12.00 ➝ $16.00High
4/19/2021Morgan StanleyLower TargetEqual Weight$14.00 ➝ $11.00Medium
3/30/2021Credit Suisse GroupInitiated CoverageOutperform$13.00High
3/3/2021Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$14.00N/A
2/25/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$14.00High
2/24/2021CitigroupLower Target$35.00 ➝ $27.00Medium
2/23/2021WedbushReiterated RatingOutperformHigh
2/5/2021SVB LeerinkReiterated RatingMarket PerformLow
12/21/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$18.00 ➝ $14.00Low
11/9/2020Morgan StanleyLower TargetOverweight$29.00 ➝ $27.00High
11/9/2020BarclaysLower TargetOverweight$33.00 ➝ $18.00High
8/5/2020Morgan StanleyLower TargetOverweight$31.00 ➝ $29.00Medium
6/19/2020SVB LeerinkLower TargetMarket Perform$18.00 ➝ $16.00High
6/19/2020Morgan StanleyBoost TargetOverweight$28.00 ➝ $31.00High
5/5/2020OppenheimerReiterated RatingHold$16.00 ➝ $17.00High
4/1/2020OppenheimerDowngradeOutperform ➝ Market Perform$17.00 ➝ $16.00High
3/4/2020BarclaysInitiated CoverageOverweight$33.00High
2/25/2020HC WainwrightReiterated RatingBuy$25.00 ➝ $36.00Low
1/24/2020Morgan StanleyBoost TargetOverweight$26.00 ➝ $28.00High
1/24/2020CowenBoost TargetOutperform$18.00 ➝ $36.00High
1/24/2020WedbushBoost TargetOutperform$24.00 ➝ $30.00High
1/23/2020CitigroupBoost TargetBuy$25.00 ➝ $35.00Medium
12/19/2019WedbushReiterated RatingOutperform$24.00High
12/5/2019Morgan StanleyUpgradeEqual Weight ➝ Overweight$12.00 ➝ $22.00High
10/31/2019HC WainwrightReiterated RatingBuyHigh
10/31/2019CowenReiterated RatingBuy$18.00Low
6/24/2019HC WainwrightSet TargetBuy$25.00Medium
6/13/2019HC WainwrightSet TargetBuy$25.00Medium
6/12/2019WedbushReiterated RatingOutperform$21.00Low
5/31/2019HC WainwrightSet TargetBuy$25.00Low
5/30/2019CitigroupReiterated RatingBuyHigh
2/27/2019Roth CapitalReiterated RatingBuyLow
2/27/2019OppenheimerLower TargetOutperform$27.00 ➝ $18.00Low
2/26/2019CowenReiterated RatingBuy$18.00Medium
1/7/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$12.00High
1/4/2019OppenheimerSet TargetBuy$27.00High
11/15/2018OppenheimerSet TargetBuy$27.00Low
11/5/2018Morgan StanleyLower TargetEqual Weight ➝ Hold$12.00 ➝ $11.00Low
11/5/2018WedbushReiterated RatingOutperform$21.00Medium
11/2/2018OppenheimerSet TargetBuy$27.00Medium
10/22/2018Roth CapitalSet TargetBuy$26.00 ➝ $18.00Low
9/25/2018SunTrust BanksBoost TargetBuy$25.00Medium
9/24/2018SVB LeerinkInitiated CoverageMarket Perform$11.00Medium
9/24/2018CowenReiterated RatingBuyHigh
9/7/2018Morgan StanleyInitiated CoverageEqual ➝ Equal WeightLow
9/7/2018Morgan StanleySet TargetEqual Weight ➝ Hold$12.00Medium
7/3/2018SVB LeerinkDowngradeOutperform ➝ Market Perform$24.00High
6/27/2018HC WainwrightReiterated RatingBuy$25.00High
5/21/2018HC WainwrightReiterated RatingBuy$25.00Low
5/18/2018WedbushBoost Target$20.00 ➝ $25.00Low
4/24/2018Roth CapitalSet TargetBuy$24.00Medium
4/24/2018SVB LeerinkSet TargetBuy$24.00High
4/24/2018WedbushLower TargetHold ➝ Outperform$24.00 ➝ $20.00High
4/24/2018SunTrust BanksLower TargetBuy ➝ Hold$20.00High
3/14/2018WedbushReiterated RatingOutperform$26.00 ➝ $25.00High
3/14/2018SVB LeerinkBoost TargetOutperform ➝ Outperform$22.00 ➝ $24.00High
3/14/2018SunTrust BanksReiterated RatingBuy$27.00High
(Data available from 2/7/2018 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/12/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/11/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/10/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/9/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/9/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/8/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/7/2023

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Epizyme logo
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $1.47
Low: $1.47
High: $1.47

50 Day Range

MA: $1.47
Low: $1.47
High: $1.52

52 Week Range

Now: $1.47
Low: $0.41
High: $5.80

Volume

7,960 shs

Average Volume

3,225,203 shs

Market Capitalization

$247.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Epizyme?

The following Wall Street research analysts have issued reports on Epizyme in the last year: Cowen Inc, Cowen Inc., HC Wainwright, StockNews.com, and Wedbush.
View the latest analyst ratings for EPZM.

What is the current price target for Epizyme?

3 Wall Street analysts have set twelve-month price targets for Epizyme in the last year. Their average twelve-month price target is $3.00, suggesting a possible upside of 104.1%. HC Wainwright has the highest price target set, predicting EPZM will reach $6.00 in the next twelve months. Cowen Inc. has the lowest price target set, forecasting a price of $1.50 for Epizyme in the next year.
View the latest price targets for EPZM.

What is the current consensus analyst rating for Epizyme?

Epizyme currently has 3 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in EPZM, but not buy more shares or sell existing shares.
View the latest ratings for EPZM.

What other companies compete with Epizyme?

How do I contact Epizyme's investor relations team?

Epizyme's physical mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company's listed phone number is (617) 229-5872 and its investor relations email address is [email protected] The official website for Epizyme is www.epizyme.com. Learn More about contacing Epizyme investor relations.